Scholarlink

<p>Hidradenitis suppurativa (HS) is a chronic inflammatory disease marked by painful nodules, abscesses, and sinus tracts, often requiring interventions such as incision and drainage (I&amp;D) or wide local excision (WLE). These procedures, common in moderate to severe cases, are invasive and prone to recurrence, underscoring the need for therapies that reduce surgical burden. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exhibit anti-inflammatory and immunomodulatory properties, with emerging evidence suggesting potential benefits for HS. The objective was to evaluate the impact of GLP-1 RA therapy on surgical outcomes in patients with HS using population-level data. A retrospective, propensity score–matched cohort analysis was performed on TriNetX comparing rates of HS-related surgical procedures in patients treated with GLP-1 RAs versus matched controls. Patients were matched 1:1 on age, gender, race, and ethnicity, resulting in two balanced cohorts of 20,672 patients each. Exposure to GLP-1 RAs was determined through prescription records, and surgical outcomes were identified using CPT codes. Odds ratios with 95% confidence intervals were included to compare the incidence of surgical intervention between groups. Simple I&amp;D was performed in 5.68% of GLP-1 RA users versus 6.54% of controls, while complicated I&amp;D occurred in 2.38% versus 2.82%. Rates of WLE were also significantly lower in the GLP-1 RA group, including axillary excision, inguinal excision, and perineal or umbilical excision. GLP-1 RA use is associated with significantly lower rates of HS-related surgical interventions in this large, propensity-matched cohort. These findings suggest a potential association between GLP-1 RA therapy and reduced surgical disease burden in HS; however, residual confounding and outcome misclassification are possible. Prospective studies are needed to confirm these findings and clarify the role of GLP-1 RAs in HS management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

GLP-1 receptor agonist therapy and surgical procedure rates in hidradenitis suppurativa

  • 期刊论文

  • 发表日期：

    2026年7月17日

查看全文
  • Kermanjot S. Sidhu,
  • Sahil Kapur,
  • Kritin Verma,
  • Sophia Gandarillas,
  • Ryan Koch,
  • Karan Pandher,
  • Iltefat Hamzavi

摘要

Hidradenitis suppurativa (HS) is a chronic inflammatory disease marked by painful nodules, abscesses, and sinus tracts, often requiring interventions such as incision and drainage (I&D) or wide local excision (WLE). These procedures, common in moderate to severe cases, are invasive and prone to recurrence, underscoring the need for therapies that reduce surgical burden. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exhibit anti-inflammatory and immunomodulatory properties, with emerging evidence suggesting potential benefits for HS. The objective was to evaluate the impact of GLP-1 RA therapy on surgical outcomes in patients with HS using population-level data. A retrospective, propensity score–matched cohort analysis was performed on TriNetX comparing rates of HS-related surgical procedures in patients treated with GLP-1 RAs versus matched controls. Patients were matched 1:1 on age, gender, race, and ethnicity, resulting in two balanced cohorts of 20,672 patients each. Exposure to GLP-1 RAs was determined through prescription records, and surgical outcomes were identified using CPT codes. Odds ratios with 95% confidence intervals were included to compare the incidence of surgical intervention between groups. Simple I&D was performed in 5.68% of GLP-1 RA users versus 6.54% of controls, while complicated I&D occurred in 2.38% versus 2.82%. Rates of WLE were also significantly lower in the GLP-1 RA group, including axillary excision, inguinal excision, and perineal or umbilical excision. GLP-1 RA use is associated with significantly lower rates of HS-related surgical interventions in this large, propensity-matched cohort. These findings suggest a potential association between GLP-1 RA therapy and reduced surgical disease burden in HS; however, residual confounding and outcome misclassification are possible. Prospective studies are needed to confirm these findings and clarify the role of GLP-1 RAs in HS management.